RT Journal Article
SR Electronic
T1 Imiquimod for superficial and in situ skin malignancy
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 113
OP 116
DO 10.1136/dtb.2009.09.0040
VO 47
IS 10
YR 2009
UL http://dtb.bmj.com/content/47/10/113.abstract
AB Relevant BNF section: 13.7 Imiquimod, an immune response modifier, is marketed as Aldara 5% cream (Meda) and licensed for treating adults with small superficial basal cell carcinomas (BCCs).1 Numerous uses outside the licensed indications (i.e. ‘off-label’) have been proposed and practised, including as treatment for pre-cancerous conditions such as Bowen's disease (squamous cell carcinoma in situ) and lentigo maligna (an in situ precursor of melanoma).2,3 Here we review the use of imiquimod for small superficial primary BCC in adults, Bowen's disease and lentigo maligna.